6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan
Our team has been working as a hub of all teams and units in our Division of Bio-Function Dynamics Imaging. Namely, we have developed a number of novel molecular probes in collaboration with laboratories of chemistry teams, clinical application unit, bio-function imaging team, cellular function imaging team, and next-generation imaging team. In particular our team focused on the development of the methodologies for molecular imaging by using macromolecular probes, such as peptides, proteins, nucleic acids, and glyco-conjugates. For evaluation of the probes and to demonstrate the usefulness of the probes, we employed several animal models of diseases and also pre-disease state such as fatigue. We also demonstrated the usefulness of PET molecular imaging in drug development; namely, pharmacokinetics (PK) studies and drug delivery systems (DDS) studies. In the other mission of our team, elaboration of PET measurement has been attempted for gaining much more accurate and highly quantitative VOI values. Then, our team is also responsible for translational research and clinical studies for stepping up the outcome of basic researches to clinical application and drug discovery.
We developed a new PET probe, [11C]dehydropravastatin, and successfully clarified the functional change of hepatobiliary transport and renal excretion caused by drug-drug interactions and genetic polymorphisms using PET with non-invasiveness and high sensitivity. Clinical research is on-going.